Core Viewpoint - Kintor Pharmaceutical (02171.HK) has signed a strategic cooperation agreement with Shanghai Jinkong Enterprise Development to invest up to 370 million yuan in building a CAR-T cell therapy product commercialization production base in Shanghai's Jinshan District, aligning with the commercialization process of multiple CAR-T products [1][2]. Group 1: Investment and Production Base - The total investment for the new CAR-T drug production base is capped at 370 million yuan, with the construction managed by Shanghai Jinkong [1]. - The investment will be executed through a phased payment model, allowing Kintor to retain cash flow for core R&D and new drug promotion [3]. - The construction is expected to take 14 months, with Kintor making quarterly service fee payments during the initial years [3]. Group 2: Product Development and Market Potential - Kintor's CAR-T product, Shurui Kiorunai, is currently under review for market approval and is the first entity-targeting CAR-T product to submit a New Drug Application in China [2]. - The product targets Claudin18.2 positive advanced gastric/esophageal junction adenocarcinoma, with clinical trial results showing superior efficacy compared to existing therapies [2]. - The market for gastric cancer treatment is significant, with 358,700 new cases and 260,400 deaths reported in 2022 in China, indicating a high demand for effective therapies [2]. Group 3: Financial Performance - Kintor expects a significant reduction in net losses, projecting a loss of no more than 120 million yuan for the reporting period, down from 798 million yuan in the previous year [4]. - The reduction in losses is attributed to increased commercialization revenue from the existing product, Zewokiorunai, and decreased R&D expenditures for both Zewokiorunai and Shurui Kiorunai [4]. - As of June 30, 2025, Kintor reported cash and bank balances of approximately 1.261 billion yuan, indicating sufficient cash flow until 2028 without considering future inflows [3].

此举紧密配合公司多款CAR-T细胞治疗产品的商业化进程，包括已上市的赛恺泽®及处于新药上市申请阶段的实体瘤 CAR-T细胞治疗产品舒瑞基奥仑赛注射液（研发代号"CT041"，拟定商品名"恺力美™"），并为多款通用型CAR-T细 胞治疗产品（如CT0596、CT1190B等）的未来量产奠定基础。在此背景下，提升符合国际标准的CAR-T细胞治疗产能 成为支撑多个产品商业化落地及增强全球竞争力的核心举措。此次交易中，本公司早期无需进行大额资本开支，有效 保留了宝贵现金流用于核心研发与市场拓展。同时，回购机制确保本公司在长期运营后可完整取得资产控制权，既维 持了生产稳定性，又强化了资产布局的灵活性。 （科济药业公众号） 2月13日，科济药业发布公告称，，公司透过其间接全资附属公司上海恺兴诊断技术有限公司，与上海市金山区湾区 高新区的重要平台企业——上海金工企业发展有限公司签署战略合作协议，总投资额不超过人民币3.7亿元，将在上海 市金山区建设先进的CAR-T细胞治疗产品商业化生产基地。 ...

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Core Viewpoint - The company expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of Zewokaiolun Injection and the acceptance of the NDA for Shurukiaolun Injection by the NMPA [1] Financial Performance - The net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zewokaiolun Injection in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in R&D expenses for both Zewokaiolun Injection and Shurukiaolun Injection [1]

Core Viewpoint - The company Kintor Pharmaceutical (02171) anticipates a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug Zeworkiobulin and the acceptance of the new drug application for Shurikiobulin by the National Medical Products Administration (NMPA) [1] Financial Performance - The expected net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Factors Influencing Loss Reduction - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in research and development expenses for both Zeworkiobulin and Shurikiobulin [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug, Zeworkiobulin Injection, and the acceptance of the New Drug Application (NDA) for Shurikiobulin Injection by the National Medical Products Administration (NMPA) [1]. Financial Summary - The net loss for the fiscal year 2025 is projected to be no more than approximately RMB 120 million, a significant decrease from approximately RMB 798 million for the fiscal year ending December 31, 2024 [1]. - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, down from approximately RMB 789 million for the fiscal year ending December 31, 2024 [1]. Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin Injection in mainland China [1]. - Impact of foreign exchange fluctuations [1]. - Significant reduction in research and development expenses for both Zeworkiobulin Injection and Shurikiobulin Injection [1].

Core Insights - Kogei Pharmaceuticals has submitted two new drug clinical trial applications for its universal BCMA CAR-T product CT0596 to the National Medical Products Administration, targeting relapsed/refractory multiple myeloma and primary plasma cell leukemia [1][17][22] - The development of universal CAR-T therapies is seen as a significant advancement in the treatment of multiple myeloma, which remains incurable despite recent therapeutic advancements [2][19] - CT0596 is developed on the THANK-u Plus platform, which enhances the product's durability and safety by gene editing to reduce the risk of graft-versus-host disease and immune rejection [4][21] Group 1: Clinical Development - CT0596 has shown promising preliminary efficacy and safety in early human studies, with 6 out of 8 patients achieving partial response or better, and no severe adverse events reported [4][21] - The submission of clinical trial applications marks the entry of CT0596 into the registration clinical development phase, potentially providing new treatment options for patients with R/R MM and pPCL [5][22] - Kogei plans to explore CT0596's application in other plasma cell tumors and plasma cell-driven autoimmune diseases [5][22] Group 2: Technological Advancements - The THANK-u Plus platform allows for immediate use and mass production of CAR-T cells, significantly reducing treatment costs compared to autologous CAR-T therapies [3][20] - Kogei has developed a robust pipeline of universal CAR-T products targeting various malignancies, including blood cancers and solid tumors, leveraging the advantages of the THANK-u Plus platform [6][23] Group 3: Market Position and Future Directions - Kogei's self-developed CAR-T product, Sazekai (Zewokaiolun), has been approved for use in relapsed or refractory multiple myeloma, with significant market penetration across over 20 provinces in China [29] - The company is actively pursuing partnerships to enhance the development and commercialization of its universal CAR-T products in mainland China [28][29] - The competitive landscape for CAR-T therapies is intensifying, with multiple companies exploring dual-target strategies and innovative delivery methods to improve patient outcomes [14][30]

Core Viewpoint - The Hong Kong innovative drug sector has experienced a significant rally this year, with the Hong Kong innovative drug index (CSI:931787) rising by 75% until October, but has since entered a cooling phase as investors digest previous gains [3][4]. Group 1: Market Performance - The innovative drug sector saw 23 companies listed in the Hong Kong healthcare sector this year, compared to only 8 last year [3]. - Despite the initial surge, many companies that have not yet entered the Stock Connect are experiencing a decline in stock prices, indicating a challenging path to inclusion [3][4]. Group 2: Stock Connect Mechanism - The Stock Connect allows mainland investors to trade Hong Kong-listed stocks, with significant contributions from southbound funds, accounting for 40%-50% of trading volume in some companies [3][4]. - Companies not included in the Stock Connect face liquidity challenges, as most mainland public funds cannot invest directly [4][5]. Group 3: Challenges for Inclusion - The threshold for entering the Stock Connect has increased due to rising market valuations, with the market capitalization requirement for inclusion in the Hang Seng Composite Index set at approximately HKD 9.32 billion [6]. - Companies previously included in the Stock Connect but later removed face significant hurdles to re-entry, as liquidity issues persist [7][8]. Group 4: Business Development (BD) Fatigue - The market has shown signs of "BD fatigue," where announcements of potential business developments no longer lead to significant stock price increases, as seen with recent collaborations that resulted in stock declines [9][10]. - Investors are now demanding more substantial evidence of project viability and commitment from partners before reacting positively to BD announcements [10]. Group 5: Future Outlook - The market is currently in a quiet phase, with investors waiting for clear signals of recovery before increasing their positions, reflecting a cautious sentiment as year-end approaches [10][11].

Core Insights - CAR-T therapy represents a revolutionary breakthrough in cancer treatment, enabling T cells to precisely identify and attack cancer cells [2] - Kintor Pharmaceutical's Shu Rui Ji Ao Lun Sai injection is poised to become the world's first CAR-T product approved for treating solid tumors, specifically targeting advanced gastric/esophageal junction adenocarcinoma [3][4] - The company is optimistic about the market potential for Shu Rui Ji Ao Lun Sai, especially given the significant unmet clinical needs in advanced gastric cancer treatment [3][4] Company Developments - Kintor Pharmaceutical's Shu Rui Ji Ao Lun Sai injection has received acceptance for new drug listing, with ongoing clinical research for indications beyond gastric cancer, including high-risk pancreatic cancer [4] - The company plans to independently commercialize Shu Rui Ji Ao Lun Sai, despite interest from multiple pharmaceutical companies for collaboration, and is currently building its commercialization team [4] - The injection has received RMAT designation from the FDA, and Kintor intends to collaborate with distributors for overseas sales [4] Industry Trends - The CAR-T market currently lacks approved products for solid tumors, with existing therapies primarily focused on hematological malignancies [3] - The high cost of CAR-T therapies, approximately 1 million yuan per treatment, limits accessibility, but recent policy changes may improve the situation through commercial health insurance [5] - Kintor is developing a universal CAR-T product to address cost and accessibility issues, aiming to reduce production costs to the range of thousands of yuan [5][6] Technological Innovations - Kintor has developed the THANK-uCAR and THANK-u Plus technology platforms to mitigate the risk of rejection associated with universal CAR-T therapies [6] - Clinical data for the second-generation universal CAR-T product CT0596 shows promising results, with a significant percentage of patients achieving partial or complete remission [6] - The company is exploring various universal CAR-T candidates targeting multiple antigens, including CLDN18.2, GPC3, and CD19/CD20, to expand treatment options [6]

Core Viewpoint - Kexing Pharmaceutical Holdings Limited has announced promising clinical data for its universal CAR-T products CT0596 and CT1190B, indicating good safety and efficacy signals for treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma [1][2] Group 1: Clinical Data and Product Development - The clinical data for CT0596 and CT1190B shows encouraging results in treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, respectively [1][2] - Kexing's universal CAR-T products can significantly reduce production costs by over 80% compared to autologous CAR-T therapies, addressing issues of high costs and patient accessibility [2] - The company has developed proprietary technology platforms, THANK-uCAR® and the upgraded THANK-u Plus®, to enhance the accessibility of CAR-T therapies and minimize immune rejection [3] Group 2: Market Context and Competitive Landscape - The current autologous CAR-T therapies are highly customized, leading to prices exceeding 1 million yuan, with only 20% of eligible patients in the U.S. able to access treatment, and an even lower percentage in China [2] - Kexing Pharmaceutical is positioned as a leading player in the domestic CAR-T therapy market, with significant achievements in the autologous CAR-T field [4] - The company aims to launch its first universal CAR-T product within the next 4-5 years, expanding treatment options for patients [3]